digital PCR
Qiagen, Exosome Dx Building Urine-Based Digital PCR Workflow for FGFR Mutations in Bladder Cancer
Premium
The firms will present a clinical comparison study using the workflow to detect FGFR mutations in 50 urothelial cancer patients later this year.
The company plans to publish new data on clinical sensitivity and specificity and has initiated multiple studies investigating new use cases.
Stilla Technologies Partners With ID-Solutions for Oncology MDx
The partners will commercialize a line of oncology mutation panels on the Stilla Naica digital PCR system.
Qiagen Reports 26 Percent Q3 Revenue Growth; Ups Full-Year Guidance
Qiagen said that growth in the quarter was primarily driven by COVID-19 testing products and improving customer demand for other products.
JP Morgan Assigns Overweight Ratings to Thermo Fisher, Qiagen
JPM moved to an Overweight rating on both companies from a Not Rated designation assigned during a restriction period as Thermo Fisher's potential acquisition of Qiagen played out.
Aug 1, 2019
Bio-Rad Q2 Revenues Down 1 Percent
Feb 28, 2019
Bio-Rad Q4 Revenues Down 1 Percent, Beat Estimates
Feb 22, 2019